生物製劑安全檢測市場：依產品類型、檢測類型、檢測方式、技術類型及地區劃分 - 趨勢與預測（至2035年）

生物製劑安全檢測市場：概要

全球生物製劑安全檢測市場預計將從目前的53億美元成長到2035年的94億美元，預測期內（至2035年）的年複合成長率（CAGR）為6.6%。

生物製劑安全檢測市場：成長與趨勢

生物製劑是由各種生物分子（例如蛋白質、碳水化合物、核酸或這些成分的混合物）組成的複雜治療藥物。生物製劑通常由活體生物生產，並且對光照、溫度、pH值和氧氣濃度等環境因素高度敏感。

由於生物來源和結構複雜性，生物製劑可能存在多種安全風險，包括免疫原性（不良免疫反應）、污染和批間差異。為解決這些問題，安全性測試非常重要，以確保治療分子不含任何有害雜質，療效可靠，且對人體應用安全。為應對這項挑戰，生物製劑安全性測試是一項嚴格的程序，目的是驗證生物製劑在臨床應用或上市前的安全性、純度、效力和一致性。受慢性病盛行率上升和個人化醫療普及推動，對先進療法的需求快速成長，預計生物製劑安全性測試市場在預測期內將保持強勁成長。

成長因素 - 市場擴張的策略驅動因素

推動生物製劑安全性測試市場發展的關鍵因素是對生物製劑和先進療法的需求不斷成長。這使得對這些產品進行全面的安全性測試變得特別必要。此外，諸如新一代定序等先進技術能夠快速檢測和識別生物製品中的雜質、污染物和安全風險。同時，監管機構也日益認識到先進的安全檢測方案在全面評估生物製品方面的重要性。因此，業界制定了全面的指導方針，要求對生物製品的污染物、免疫原性、病毒安全性和生產一致性進行廣泛的檢測。

市場挑戰 - 阻礙發展的重大障礙

生物製品安全檢測市場持續成長，但仍存在一些挑戰阻礙其廣泛應用。複雜的設備、試劑和內部檢測能力帶來的高昂成本對中小企業造成了沉重負擔，限制了它們的市場滲透率，並增加了它們對外包的依賴。此外，複雜且具地域性的法規會導致合規延遲、審批流程冗長，並因標準差異而增加研發成本。生物製劑日益複雜，推動了檢測需求的成長，但永續性問題在未能充分解決成本問題的情況下，也帶來了營運方面的挑戰。

生物製劑安全檢測市場 - 關鍵洞察

本報告深入分析了生物製劑安全檢測市場的現狀，並指出了該行業的潛在成長機會。主要發現包括：

• 60%的生物製劑安全檢測服務提供者提供內毒素檢測服務。值得注意的是，約55%的服務提供者採用各種技術來評估疫苗的安全性。

• 為了追求競爭優勢並滿足不斷變化的行業需求，利害關係人改進其服務組合併積極提升現有能力。
• 全球約有 40 家公司提供生物製品安全檢測解決方案。值得注意的是，超過 80%的生物製品安全檢測提供者提供研究用途的解決方案。
• 目前，超過 75%的生物製品安全檢測解決方案提供者使用聚合酶鍊式反應（PCR）技術，50%的解決方案提供者致力於提供細胞療法安全檢測解決方案。
• 為了確保病人安全並滿足嚴格的監管要求，行業利益相關者積極創新和開發可供各種終端用戶使用的生物製品安全檢測解決方案。
• 該領域完成的大部分交易都是收購，這表明其戰略重點在於擴大市場覆蓋範圍，並確保在不同地區都能獲得專業的生物安全檢測解決方案。
• 過去幾年，生物製品安全檢測解決方案提供商透過多輪融資籌集了超過 52億美元的資金，其中超過 90%的資金來自北美公司。

• 在過去兩年中，與生物製品安全檢測相關的專利約有 40%獲得授權，其中絕大多數專利（89%）由產業參與者提交。
• 預計到2035年，生物製劑安全檢測市場將保持穩定成長，其中耗材預計將在不久的將來佔據大部分市場佔有率（超過60%）。
• 目前，抗體細分市場佔據了大部分市場佔有率。這主要得益於單株抗體的廣泛應用，單株抗體在癌症、自體免疫疾病和傳染病的標靶治療中發揮重要作用。
• 美國生物製劑安全檢測市場的主要驅動因素是生物製劑日益複雜化以及需要進行生物製劑安全檢測的慢性疾病盛行率不斷上升。
• 預計到2035年，生物製劑安全檢測市場將以約7.1%的年複合成長率成長。其中，生物製劑安全檢測耗材預計將佔據大部分市場佔有率（約60%）。

• 複雜生物製品的快速發展，加上技術的進步，使生物製品安全檢測產業在未來具有良好的成長前景。

生物製品安全檢測市場

市場規模和機會分析基於以下參數進行細分：

依產品類型

• 耗材
• 設備
• 服務

依檢測類型

• 病毒安全檢測
• 支原體檢測
• 無菌檢測
• 內毒素檢測
• 生物負荷檢測
• 其他檢測

依安全性類型

• 抗體
• 疫苗
• 細胞療法
• 基因療法
• 生物相似藥
• 傳統病毒療法
• 蛋白質
• 其他療法

依技術類型

• 聚合酶鍊式反應（PCR）
• 傳統技術
• 色譜與電泳技術
• 次世代定序
• 其他技術

依最終使用者

• 製藥和生技公司
• 合約研究組織/合約開發與生產組織
• 學術和研究機構

依地區

• 北美
• 美國
• 加拿大
• 歐洲
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 歐洲其他地區
• 亞太地區
• 中國
• 日本
• 印度
• 韓國
• 亞太其他地區
• 中東和北非非洲
• 沙烏地阿拉伯
• 埃及
• 其他中東和北非國家
• 拉丁美洲
• 巴西
• 阿根廷
• 其他拉丁美洲國家

生物製品安全檢測市場：主要細分市場

耗材佔據生物製品安全偵測市場最大佔有率

根據生物製品安全檢測市場分析，耗材細分市場佔據主導地位（60%），這主要得益於生物製品安全檢測所需耗材需求的不斷成長。此外，儀器的年複合成長率預計更高，在預測期內展現出顯著的成長潛力。這主要歸功於能夠提高工作流程效率並減少人為錯誤的儀器的引進。

未來病毒安全性檢測將佔據最大佔有率

生物製劑安全性檢測市場預測顯示，病毒安全性檢測區隔市場將佔最大佔有率（約30%）。這主要受慢性疾病發生率上升和新型生物療法接受度提高的推動。預計支原體檢測在預測期內將以較高的年複合成長率成長，展現出巨大的成長潛力。這一成長主要得益於嚴格的監管要求，即在生物製劑生產過程中必須對支原體污染進行徹底檢測。 今年，抗體細分市場將佔據生物製劑安全性檢測市場的最大佔有率。 市場分析顯示，抗體細分市場約佔生物製劑安全性檢測市場的35%。其領先地位主要歸功於其卓越的特異性、適應性和經證實的有效性。此外，疫苗具有廣泛的治療應用，包括腫瘤、自體免疫疾病和傳染病等領域，催生了對生物製劑安全性檢測的需求。預計在預測期內，疫苗的年複合成長率將更高，展現出巨大的成長潛力。這一成長與疫苗獲批數量的增加以及針對各種靶向適應症的持續研究密切相關。

今年，聚合酶鍊式反應（PCR）將佔據生物製劑安全性檢測市場最大的佔有率。

該市場依技術類型細分，包括聚合酶鍊式反應（PCR）、傳統方法、色譜和電泳、下一代定序以及其他技術。今年，聚合酶鍊式反應（PCR）子領域佔據了生物製劑安全性檢測市場約 35%的顯著佔有率。這項優勢得益於聚合酶鍊式反應技術的最新進展。該技術具有更高的準確性、絕對定量能力以及同時檢測多個標靶的能力，提高了檢測效率和可靠性。此外，PCR技術易於實現高通量篩選的自動化，可以同時檢測多種污染物。這種自動化非常重要。提高生物製品安全檢測實驗室的營運效率並降低檢測成本。

北美市場佔主導地位，佔有率最大

生物製品安全檢測市場分析預測，由於先進分子檢測技術的日益普及，製藥和生物技術公司今年將佔據生物製品安全檢測市場的大部分佔有率（約 50%）。這得歸功於它們強大的研發能力、大量的資本投資以及目的是應對日益嚴峻的全球健康挑戰的創新生物製品研發管線。預計製藥和生物技術公司在預測期內將實現 7.8%的高年複合成長率，表明其具有強勁的成長潛力。

生物製品安全檢測市場主要參與者

• BioMerieux
• Charles River Laboratories
• Clean Cells
• Eurofins
• Genezen
• SGS
• Solvias
• Texcell
• Vimta Labs
• Wickham Micro

生物製品安全檢測市場：研究範圍

• 市場規模和機會分析：本報告對生物製品安全檢測市場進行了詳細分析，重點關注以下關鍵市場細分：[A] 交付形式，[B] 檢測類型，[C] 模式類型，[D] 技術類型，以及 [E] 地理區域。
• 生物製品安全檢測服務提供者市場概覽：除了對整個生物製品安全檢測服務提供商市場進行全面的市場概覽外，本報告還提供了有關相關參數的詳細資訊，例如：[A] 成立年份，[B] 公司規模，[C] 總部所在地，[D] 認證/認可，[E] 服務類型，[F] 檢測方法
• 生物製品安全偵測服務提供者競爭分析：基於以下三個面向對生物製品安全偵測服務提供者進行深入分析：[A] 供應商優勢，[B] 服務優勢，以及 [C] 產品組合多樣性。
• 生物製品安全檢測解決方案提供者市場概覽：除了對生物製品安全檢測服務提供者市場的整體評估外，本報告還包含以下資訊：[A] 成立年份，[B] 公司規模，[C] 總部所在地，[D] 服務類型，[E] 檢測類型，[F] 實施方法類型，[G] 分析的樣本，[H] 技術類型。
• 生物製品安全檢測解決方案提供者競爭分析：基於 [A] 供應能力，[B] 服務能力，以及 [C] 產品組合多樣性，對生物製品安全檢測解決方案提供者進行深入分析。
• 公司簡介：基於 [A] 成立年份，[B] 總部所在地，[C] 產品組合，[D] 近期發展，以及 [E] 未來展望，對北美、歐洲和亞太地區從事生物製品安全檢測領域的主要公司進行詳細介紹。
• 合作夥伴關係與合作：基於多個相關參數（例如[A] 合作年份、[B] 合作類型、[C] 合作夥伴類型和[F] 最活躍參與者）分析利害關係人之間達成的合作夥伴關係與合作。
• 資金與投資分析：基於相關參數（例如[A] 資金年份、[B] 投資金額、[C] 資金類型、[D] 地域分佈和[E] 最活躍參與者）詳細分析參與生物製品安全檢測市場的利害關係人的資金和投資狀況。
• 專利分析：基於多個相關參數（例如[A] 公開年份、[B] 專利類型、[C] 申請年份、[D] 專利管轄區和[E] 主要持有人）詳細分析與生物製品安全檢測相關的各項專利。
• 市場影響分析：詳細分析可能影響生物製品安全檢測市場成長的因素。它還包括以下方面的識別和市場分析：[A]關鍵驅動因素，[B]潛在限制因素，[C]新興機會，以及[D]現有挑戰。

目錄

第1章 報告概述

第2章 研究方法

第3章 市場動態

第4章 宏觀經濟指標

第5章 執行摘要

第6章 引言

• 生物安全檢測概述
• 主要生物安全檢測
• 生物安全領域面臨的挑戰
• 生物安全檢測領域的最新趨勢
• 未來展望

第7章 市場格局：生物安全偵測服務供應商

• 研究方法及關鍵指標參數
• 生物安全檢測服務提供者：市場概況

第8章 競爭分析：生物製品安全偵測服務提供者

• 研究方法與關鍵參數
• 評分標準
• 同儕比較
• 生物製品安全偵測服務提供者：競爭分析

第9章 市場概況：生物製品安全檢測解決方案提供者

• 研究方法與關鍵參數
• 生物製品安全檢測解決方案提供者：市場概況

第10章 競爭分析：生物製品安全偵測解決方案提供者

• 研究方法與關鍵參數
• 評分標準
• 同儕比較
• 生物製品安全檢測解決方案供應商：競爭分析

第11章 公司簡介：生物製品安全偵測供應商

• 章節概述
• BioMerieux
• Charles River Laboratories
• Clean Cells
• Eurofins
• Genezen
• SGS
• Solvias
• Texcell
• Vimta Labs
• Wickham Micro

第12章 合作關係

• 合作模式
• 生物安全檢測：合作關係

第13章 資金與投資

第14章 專利分析

第15章 市場影響分析

• 市場驅動因素
• 市場限制
• 市場機會
• 市場挑戰

第16章 全球生物製品安全偵測市場

• 關鍵假設與研究方法
• 全球生物製品安全檢測市場：歷史趨勢（2021年及以後）與預測（至2035年）
  • 情境分析
• 主要市場區隔

第17章 生物製品安全檢測市場（依服務類型劃分）

第18章 生物製品安全檢測市場（依研究類型劃分）

第19章 生物製品安全檢測市場（依檢測方式劃分）

第20章 生物製品安全檢測市場（依技術劃分）

第21章 生物製品安全檢測市場（依最終用戶劃分）

第22章 生物製品安全檢測市場（依地區劃分）

第23章 市場機會分析：北美

第24章 市場機會分析：歐洲

第25章 市場機會分析：亞太地區

第26章 市場機會分析：中東與北非

第27章 市場機會分析：拉丁美洲

第28章 波特五力分析

第29章 結論

第30章 高層洞察

第31章 附錄1：表格資料

第32章 公司與組織清單

Biologics Safety Testing Market: Overview

As per Roots Analysis, the global biologics safety testing market is estimated to grow from USD 5.3 billion in the current year to USD 9.4 billion by 2035, at a CAGR of 6.6% during the forecast period, till 2035.

Biologics Safety Testing Market: Growth and Trends

Biologics are intricate therapeutic agents made up of different biomolecules, including proteins, carbohydrates, nucleic acids, or a mix of these components. Biologics are typically produced by living organisms and are extremely responsive to environmental influences, such as light, temperature, pH, and oxygen concentrations.

Biologics can present various safety risks due to their biological origin and structural complexity, including immunogenicity (undesired immune reactions), contamination, and variability between batches. To tackle these issues, safety testing is essential for confirming that these therapeutic molecules are devoid of hazardous impurities, reliably effective, and safe for human application. To tackle this, biologics safety testing is a rigorous procedure aimed at verifying biologic safety, purity, potency, and consistency prior to clinical application or market launch. Driven by surging demand for advanced therapies amid rising chronic disease prevalence and personalized medicine adoption, the biologics safety testing market is poised for robust growth during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

Key factors driving the biologics safety testing market include the increasing demand for biologics and advanced therapies, which creates a need for thorough safety testing of these products. Moreover, cutting-edge technologies like next generation sequencing allow for quicker detection and identification of impurities, contaminants, and safety risks in biologics. Furthermore, regulatory agencies are becoming more aware of the importance of advanced safety testing protocols for the thorough assessment of biologic products. As a result, they are establishing comprehensive guidelines that necessitate extensive testing for contaminants, immunogenicity, viral safety, and consistency in the manufacturing of biologics.

Market Challenges: Critical Barriers Impeding Progress

Challenges continue to exist in the biologics safety testing market, even with its ongoing growth, which obstructs quicker adoption. The high costs associated with advanced equipment, reagents, and internal capabilities strain small to mid-sized companies, limiting their market reach and increasing their dependence on outsourcing. Additionally, intricate and region-specific regulations lead to compliance delays, longer approval processes, and increased development costs due to varying standards. The increasing complexity of biologics raises the demands for testing, while sustainability concerns introduce operational challenges without adequately addressing the cost issues.

Biologics Safety Testing Market: Key Insights

The report delves into the current state of the biologics safety testing market and identifies potential growth opportunities within industry. Some key findings from the report include:

• 60% of the biologics safety testing service providers offer endotoxin testing services; interestingly, close to 55% of the service providers are employing various technologies to evaluate safety profile of vaccines.

• In pursuit of gaining a competitive edge and to meet the evolving industry requirements, stakeholders are actively enhancing their existing capabilities by improving their respective service portfolios.
• Close to 40 companies are engaged in offering biologics safety testing solutions across the globe; notably, over 80% of the biologics safety testing providers offer solutions for research purpose.
• Presently, more than 75% of the biologics safety testing solution providers use polymerase chain reaction technique; 50% of the solution providers claim to offer safety testing solutions for cell therapies.
• Industry stakeholders are actively innovating and developing biologics safety testing solutions that can be utilized by various end-users to ensure patient safety and meet stringent regulatory requirements.
• Majority of the deals inked in this domain were acquisitions, indicating a strategic focus on expanding market reach and ensuring availability of specialized biosafety testing solutions across diverse geographic regions.
• In the past few years, over USD 5.2 billion has been raised by biologics safety testing solution providers across various funding rounds; of these, >90% of the total amount was raised by players based in North America.

• Close to 40% of the patents have been granted related to biologics safety testing in the last two years; further, most of the patents have been filed by industry players (89%).
• The biologics safety testing market is anticipated to grow at a steady rate, till 2035; consumables are expected to capture the majority share (more than 60%) of the market in foreseeable future.
• Currently, majority of the market share is captured by antibodies subsegment owing to the widespread use of monoclonal antibodies, which play a vital role in targeted therapies for cancer, autoimmune, and infectious diseases.
• The US biologics safety testing market is primarily driven by the rising number of complex biologics and prevalence of chronic disorders necessitating the need for biologics safety testing.
• The biologics safety testing market is likely to grow at an annualized rate (CAGR) of ~7.1%, till 2035; majority of the market share (~60%) is expected to be captured by biologics safety testing consumables.

• Given the surge in development of complex biologics, combined with technological advancements, the biologics safety testing industry is well-positioned for future growth.

Biologics Safety Testing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Offering

• Consumables
• Instruments
• Services

By Type of Testing

• Virus Safety Testing
• Mycoplasma Testing
• Sterility Testing
• Endotoxin Testing
• Bioburden Testing
• Other Testing

By Type of Modality

• Antibodies
• Vaccines
• Cell Therapies
• Gene Therapies
• Biosimilars
• Traditional viral-based Therapies
• Proteins
• Other Modalities

By Type of Technology

• Polymerase Chain Reaction
• Traditional Techniques
• Chromatographic and Electrophoretic Techniques
• Next-Generation Sequencing
• Other Technologies

By End-user

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations / Contract Development and Manufacturing Organizations
• Academic and Research Institutes

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Rest of Asia-Pacific
• Middle East and North Africa
• Saudi Arabia
• Egypt
• Rest of Middle East and North Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Biologics Safety Testing Market: Key Segments

Consumables Account for the Largest Biologics Safety Testing Market Share

According to the biologics safety testing market analysis, the consumables sub-segment dominates the market (60%), driven by the increased demand for consumables, essential for biologics safety testing. Further, instruments are likely to grow at a higher CAGR, showcasing substantial growth potential during the forecast period. This is because the adoption of instruments can streamline the overall workflow and reduce human error.

Virus Safety Testing Hold the Highest Share in the Future

The forecast for the biologics safety testing market indicates that the virus safety testing sub-segment holds the largest share (approximately 30%), fueled by the increasing incidence of chronic illnesses and the growing acceptance of novel biologic treatments. Mycoplasma testing is expected to experience a higher compound annual growth rate (CAGR), demonstrating significant growth opportunities during the forecast period. This growth is largely attributed to stringent regulatory requirements that necessitate thorough testing for mycoplasma contamination in the production of biologics.

Antibodies Segment Holds the Highest Biologics Safety Testing Market Share in the Current Year

As per market analysis, the antibodies sub-segment represents approximately 35% of the biologics safety testing market share. This leading position is largely attributed to their remarkable specificity, adaptability, and proven efficiency. Furthermore, they possess a wide array of therapeutic uses, including in the fields of oncology, autoimmune disorders, and infectious diseases, which creates a demand for biological safety testing. Vaccines are expected to experience a higher compound annual growth rate (CAGR), indicating significant growth potential throughout the forecast period. This increase can be linked to the rising number of vaccine approvals and their ongoing investigation for various target indications.

Polymerase Chain Reaction Holds the Highest Biologics Safesty Testing Market Share in the Current Year

The overall market is segmented into various technology types, including polymerase chain reaction, traditional methods, chromatographic and electrophoretic methods, next-generation sequencing, and other technologies. The polymerase chain reaction sub-segment holds a significant share of the biologics safety testing market (~35%) this year. This dominance is attributed to recent advancements in polymerase chain reaction technology that provide greater accuracy, absolute quantification, and the capability to detect multiple targets simultaneously, thus improving testing efficiency and reliability. Additionally, the ease of automating PCR technologies for high-throughput screening allows for the simultaneous detection of several contaminants. Such automation enhances operational efficiency and lowers testing costs for biological safety testing laboratories.

North America Dominates the Market by Securing Highest Share

As per the analysis of the biologics safety testing market, the growing implementation of advanced molecular testing technologies is expected to enable pharmaceutical and biotechnology firms to capture a significant portion of the biologics safety testing market (approximately 50% share) in the current year. This is attributed to their strong capabilities in research and development (R&D), considerable financial investments, and robust pipelines of innovative biologics designed to meet the increasing global health challenges. Pharmaceutical and biotechnology firms are predicted to experience a higher compound annual growth rate (CAGR) of 7.8%, indicating considerable growth potential throughout the forecast period.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:

• Business Development Officer, Mid-sized Organization, Austria
• Business Development Director, Mid-sized Organization, Poland

In addition, the market report includes transcripts of the following other third-party discussions:

• R&D Scientist and Product Manager, Very Large Organization, Germany
• Scientific Expert, Very Large Organization, United States

Example Players in Biologics Safety Testing Market

• BioMerieux
• Charles River Laboratories
• Clean Cells
• Eurofins
• Genezen
• SGS
• Solvias
• Texcell
• Vimta Labs
• Wickham Micro

Biologics Safety Testing Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the biologics safety testing market, focusing on key market segments, including [A] type of offering [B] type of testing, [C] type of modality, [D] type of technology, and [E] geographical regions.
• Biologics Safety Testing Service Providers Market Landscape: A detailed assessment of the overall biologics safety testing service providers market landscape, along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] certification / accreditation, [E] type of service offered [F] type of modality, [G] type of sample supported, [H type of technology, and [I] end user.
• Competitiveness Analysis of Biologics Safety Testing Service Providers: An insightful analysis of biologics safety testing service providers based on the [A] supplier strength and [B] service strength and [C] portfolio diversity.
• Biologics Safety Testing Solution Providers Market Landscape: A detailed assessment of the overall biologics safety testing service providers market landscape, along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of offering, [E] type of testing [F] type of modality, [G] type of sample analyzed, [H type of technology, [I] application area and [J] end user.
• Competitiveness Analysis of Biologics Safety Testing Solution Providers: An insightful analysis of biologics safety testing solution providers based on the [A] supplier strength and [B] service strength and [C] portfolio diversity.
• Company Profiles: In-depth profiles of leading players engaged in biologics safety testing domain in North America, Europe and Asia-Pacific based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships and collaborations inked between stakeholders, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, and [F] most active players.
• Funding and Investment Analysis: A detailed analysis of the funding and investments raised by stakeholders engaged in the biologics safety testing market, based on several relevant parameters, such as [A] year of funding, [B] amount invested, [C] type of funding, [D] regional distribution, [E] and most active players.
• Patent Analysis: an in-depth analysis of various patents that have been filed / granted for biologics safety testing based on several relevant parameters, such as [A] publication year, [B] type of patent, [C] application year, [D] patent jurisdiction, [E] and leading individual assignees.
• Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the biologics safety testing market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

• Which are the leading companies in biologics safety testing market?
• Which region dominates the biologics safety testing market?
• What are the key trends observed in the biologics safety testing market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by biologics safety testing service providers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary PPT Insights Pack
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1 REPORT OVERVIEW

• 1.1. Context
• 1.2. Project Objectives

2 RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3 MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4 MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product (GDP)
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross-Border Dynamics
• 4.3. Conclusion

5 EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6 INTRODUCTION

• 6.1. Overview of Biologics Safety Testing
• 6.2. Key Biosafety Tests
• 6.3. Challenges in the Biologics Safety Domain
• 6.4. Recent Developments in the Biologics Safety Testing Domain
• 6.5. Future Perspectives

7 MARKET LANDSCAPE: BIOLOGICS SAFETY TESTING SERVICE PROVIDERS

• 7.1. Methodology and Key Parameters
• 7.2. Biologics Safety Testing Service Providers: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Certification / Accreditation
  • 7.2.5. Analysis by Type of Service Offered
  • 7.2.6. Analysis by Type of Modality
  • 7.2.7. Analysis by Type of Sample Supported
  • 7.2.8. Analysis by Type of Technology
  • 7.2.9. Analysis by End-user

8 COMPANY COMPETITIVENESS ANALYSIS: BIOLOGICS SAFETY TESTING SERVICE PROVIDERS

• 8.1. Methodology and Key Parameters
• 8.2. Scoring Criteria
• 8.3. Peer Groups
• 8.4. Biologics Safety Testing Service Providers: Company Competitiveness Analysis
  • 8.4.1. Biologics Safety Testing Service Providers Offering Services for Vaccines
  • 8.4.2. Biologics Safety Testing Service Providers Offering Services for Cell Therapies
  • 8.4.3. Biologics Safety Testing Service Providers Offering Services for Gene Therapies
  • 8.4.4. Biologics Safety Testing Service Providers Offering Services for Antibodies
  • 8.4.5. Biologics Safety Testing Service Providers Offering Services for Proteins
  • 8.4.6. Biologics Safety Testing Service Providers Offering Services for Other Modalities

9 MARKET LANDSCAPE: BIOLOGICS SAFETY TESTING SOLUTION PROVIDERS

• 9.1. Methodology and Key Parameters
• 9.2. Biologics Safety Testing Solution Providers: Overall Market Landscape
  • 9.2.1. Analysis by Year of Establishment
  • 9.2.2. Analysis by Company Size
  • 9.2.3. Analysis by Location of Headquarters
  • 9.2.4. Analysis by Type of Offering
  • 9.2.5. Analysis by Type of Testing
  • 9.2.6. Analysis by Type of Modality
  • 9.2.7. Analysis by Type of Sample Analyzed
  • 9.2.8. Analysis by Type of Technology
  • 9.2.9. Analysis by Application Area
  • 9.2.10. Analysis by End-user

10 COMPANY COMPETITIVENESS ANALYSIS: BIOLOGICS SAFETY TESTING SOLUTION PROVIDERS

• 10.1. Methodology and Key Parameters
• 10.2. Scoring Criteria
• 10.3. Peer Groups
  • 10.3.1. Overview of Peer Groups
• 10.4. Biologics Safety Testing Solution Providers: Company Competitiveness Analysis
  • 10.4.1. Biologics Safety Testing Solution Providers Headquartered in North America
  • 10.4.2. Biologics Safety Testing Solution Providers Headquartered in Europe
  • 10.4.3. Biologics Safety Testing Solution Providers Headquartered in Asia-Pacific and Rest of the world

11 COMPANY PROFILES: BIOLOGICS SAFETY TESTING PROVIDERS

• 11.1. Chapter Overview
• 11.2. BioMerieux
  • 11.2.1. Company Overview
  • 11.2.2. Service Portfolio
  • 11.2.3. Financial Information
  • 11.2.4. Recent Developments and Future Outlook
• 11.3. Charles River Laboratories
• 11.4. Clean Cells
• 11.5. Eurofins
• 11.6. Genezen
• 11.7. SGS
• 11.8. Solvias
• 11.9. Texcell
• 11.10. Vimta Labs
• 11.11. Wickham Micro

12 PARTNERSHIPS AND COLLABORATIONS

• 12.1. Partnership Models
• 12.2. Biologics Safety Testing: Partnerships and Collaborations
  • 12.2.1. Analysis by Year of Partnership
  • 12.2.2. Analysis by Type of Partnership
  • 12.2.3. Analysis by Year and Type of Partnership
  • 12.2.4. Analysis by Type of Biologic
  • 12.2.5. Analysis by Type of Testing
  • 12.2.6. Analysis by Type of Partner
  • 12.2.7. Most Active Players: Analysis by Number of Partnerships
  • 12.2.8. Analysis by Geography
    • 12.2.8.1. Local and International Deals
    • 12.2.8.2. Intracontinental and Intercontinental Deals

13 FUNDING AND INVESTMENTS

• 13.1. Funding Models
• 13.2. Funding Lifecycle Analysis
• 13.3. Investment Case: Risk and Return
• 13.4. Biologics Safety Testing: Funding and Investments
  • 13.4.1. Analysis of Instances by Year of Funding
  • 13.4.2. Analysis of Instances by Type of Funding
  • 13.4.3. Analysis of Instances by Year and Type of Funding
  • 13.4.4. Analysis of Amount by Year of Funding
  • 13.4.5. Analysis of Amount by Type of Funding
  • 13.4.6. Analysis by Geography
  • 13.4.7. Key Industry Players: Analysis by Number of Funding Instances
  • 13.4.8. Most Active Players: Analysis by Amount Invested
  • 13.4.9. Most Active Investors: Analysis by Number of Funding Instances
  • 13.4.10. Summary of Investments

14 PATENT ANALYSIS

• 14.1. Methodology and Key Parameters
• 14.2. Biologics Safety Testing: Patent Analysis
  • 14.2.1. Analysis by Publication Year
  • 14.2.2. Analysis by Type of Patent
  • 14.2.3. Analysis by Patent Application Year
  • 14.2.4. Analysis by Patent Age
  • 14.2.5. Analysis by Type of Applicant
  • 14.2.6. Analysis by Patent Jurisdiction
  • 14.2.7. Analysis by CPC Symbols
  • 14.2.8. Leading Industry Players: Analysis by Number of Patents
  • 14.2.9. Leading Non-Industry Players: Analysis by Number of Patents
  • 14.2.10. Leading Individual Assignees: Analysis by Number of Patents
• 14.3. Biologics Safety Testing: Patent Benchmarking
• 14.4. Biologics Safety Testing: Patent Valuation

15 MARKET IMPACT ANALYSIS

• 15.1. Market Drivers
• 15.2. Market Restraints
• 15.3. Market Opportunities
• 15.4. Market Challenges

16 GLOBAL BIOLOGICS SAFETY TESTING MARKET

• 16.1. Key Assumptions and Methodology
• 16.2. Global Biologics Safety Testing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 16.2.1. Scenario Analysis
    • 16.2.1.1. Conservative Scenario
    • 16.2.1.2. Optimistic Scenario
• 16.3. Key Market Segments

17 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF OFFERING

• 17.1. Key Assumptions and Methodology
• 17.2. Biologics Safety Testing Market: Distribution by Type of Offering
  • 17.2.1. Biologics Safety Testing Market for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.2.2. Biologics Safety Testing Market for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 17.2.3. Biologics Safety Testing Market for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF TESTING

• 18.1. Key Assumptions and Methodology
• 18.2. Biologics Safety Testing Market: Distribution by Type of Testing
  • 18.2.1. Biologics Safety Testing Market for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.2. Biologics Safety Testing Market for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.3. Biologics Safety Testing Market for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.4. Biologics Safety Testing Market for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.5. Biologics Safety Testing Market for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 18.2.6. Biologics Safety Testing Market for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF MODALITY

• 19.1. Key Assumptions and Methodology
• 19.2. Biologics Safety Testing Market: Distribution by Type of Modality
  • 19.2.1. Biologics Safety Testing Market for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.2. Biologics Safety Testing Market for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.3. Biologics Safety Testing Market for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.4. Biologics Safety Testing Market for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.5. Biologics Safety Testing Market for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.6. Biologics Safety Testing Market for Traditional viral-based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.7. Biologics Safety Testing Market for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.2.8. Biologics Safety Testing Market for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20 BIOLOGICS SAFETY TESTING MARKET, BY TYPE OF TECHNOLOGY

• 20.1. Key Assumptions and Methodology
• 20.2. Biologics Safety Testing Market: Distribution by Type of Technology
  • 20.2.1. Biologics Safety Testing Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.2. Biologics Safety Testing Market for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.3. Biologics Safety Testing Market for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.4. Biologics Safety Testing Market for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.2.5. Biologics Safety Testing Market for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21 BIOLOGICS SAFETY TESTING MARKET, BY END-USER

• 21.1. Key Assumptions and Methodology
• 21.2. Biologics Safety Testing Market: Distribution by End-user
  • 21.2.1. Biologics Safety Testing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 21.2.2. Biologics Safety Testing Market for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 21.2.3. Biologics Safety Testing Market for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22 BIOLOGICS SAFETY TESTING MARKET, BY GEOGRAPHICAL REGIONS

• 22.1. Key Assumptions and Methodology
• 22.2. Biologics Safety Testing Market: Distribution by Geographical Regions
  • 22.2.1. Biologics Safety Testing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.1.1. Biologics Safety Testing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.1.2. Biologics Safety Testing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.2. Biologics Safety Testing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.1. Biologics Safety Testing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.2. Biologics Safety Testing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.3. Biologics Safety Testing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.4. Biologics Safety Testing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.5. Biologics Safety Testing Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.2.6. Biologics Safety Testing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.3. Biologics Safety Testing Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.1. Biologics Safety Testing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.2. Biologics Safety Testing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.3. Biologics Safety Testing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.4. Biologics Safety Testing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.3.5. Biologics Safety Testing Market in Rest of Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.4. Biologics Safety Testing Market in Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.4.1. Biologics Safety Testing Market in Saudi Arabia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.4.2. Biologics Safety Testing Market in Egypt, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.4.3. Biologics Safety Testing Market in Rest of Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.2.5. Biologics Safety Testing Market in Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.5.1. Biologics Safety Testing Market in Brazil, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.5.2. Biologics Safety Testing Market in Argentina, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 22.2.5.3. Biologics Safety Testing Market in Rest of Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23 MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 23.1. Biologics Safety Testing Market in North America: Distribution by Type of Offering
  • 23.1.1. Biologics Safety Testing Market in North America for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.1.2. Biologics Safety Testing Market in North America for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.1.3. Biologics Safety Testing Market in North America for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.2. Biologics Safety Testing Market in North America: Distribution by Type of Testing
  • 23.2.1. Biologics Safety Testing Market in North America for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.2. Biologics Safety Testing Market in North America for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.3. Biologics Safety Testing Market in North America for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.4. Biologics Safety Testing Market in North America for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.5. Biologics Safety Testing Market in North America for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.2.6. Biologics Safety Testing Market in North America for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.3. Biologics Safety Testing Market in North America: Distribution by Type of Modality
  • 23.3.1. Biologics Safety Testing Market in North America for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.2. Biologics Safety Testing Market in North America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.3. Biologics Safety Testing Market in North America for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.4. Biologics Safety Testing Market in North America for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.5. Biologics Safety Testing Market in North America for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.6. Biologics Safety Testing Market in North America for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.7. Biologics Safety Testing Market in North America for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.8. Biologics Safety Testing Market in North America for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.4. Biologics Safety Testing Market in North America: Distribution by Type of Technology
  • 23.4.1. Biologics Safety Testing Market in North America for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.2. Biologics Safety Testing Market in North America for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.3. Biologics Safety Testing Market in North America for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.4. Biologics Safety Testing Market in North America for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.4.5. Biologics Safety Testing Market in North America for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.5. Biologics Safety Testing Market in North America: Distribution by End-user
  • 23.5.1. Biologics Safety Testing Market in North America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.5.2. Biologics Safety Testing Market in North America for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.5.3. Biologics Safety Testing Market in North America for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

24 MARKET OPPORTUNITY ANALYSIS: EUROPE

• 24.1. Biologics Safety Testing Market in Europe: Distribution by Type of Offering
  • 24.1.1. Biologics Safety Testing Market in Europe for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.1.2. Biologics Safety Testing Market in Europe for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.1.3. Biologics Safety Testing Market in Europe for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.2. Biologics Safety Testing Market in Europe: Distribution by Type of Testing
  • 24.2.1. Biologics Safety Testing Market in Europe for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.2. Biologics Safety Testing Market in Europe for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.3. Biologics Safety Testing Market in Europe for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.4. Biologics Safety Testing Market in Europe for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.5. Biologics Safety Testing Market in Europe for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.2.6. Biologics Safety Testing Market in Europe for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.3. Biologics Safety Testing Market in Europe: Distribution by Type of Modality
  • 24.3.1. Biologics Safety Testing Market in Europe for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.2. Biologics Safety Testing Market in Europe for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.3. Biologics Safety Testing Market in Europe for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.4. Biologics Safety Testing Market in Europe for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.5. Biologics Safety Testing Market in Europe for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.6. Biologics Safety Testing Market in Europe for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.7. Biologics Safety Testing Market in Europe for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.8. Biologics Safety Testing Market in Europe for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.4. Biologics Safety Testing Market in Europe: Distribution by Type of Technology
  • 24.4.1. Biologics Safety Testing Market in Europe for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.2. Biologics Safety Testing Market in Europe for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.3. Biologics Safety Testing Market in Europe for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.4. Biologics Safety Testing Market in Europe for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.5. Biologics Safety Testing Market in Europe for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.5. Biologics Safety Testing Market in Europe: Distribution by End-user
  • 24.5.1. Biologics Safety Testing Market in Europe for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.5.2. Biologics Safety Testing Market in Europe for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.5.3. Biologics Safety Testing Market in Europe for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

25 MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

• 25.1. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Offering
  • 25.1.1. Biologics Safety Testing Market in Asia-Pacific for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.1.2. Biologics Safety Testing Market in Asia-Pacific for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.1.3. Biologics Safety Testing Market in Asia-Pacific for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.2. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Testing
  • 25.2.1. Biologics Safety Testing Market in Asia-Pacific for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.2. Biologics Safety Testing Market in Asia-Pacific for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.3. Biologics Safety Testing Market in Asia-Pacific for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.4. Biologics Safety Testing Market in Asia-Pacific for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.5. Biologics Safety Testing Market in Asia-Pacific for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.2.6. Biologics Safety Testing Market in Asia-Pacific for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.3. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Modality
  • 25.3.1. Biologics Safety Testing Market in Asia-Pacific for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.2. Biologics Safety Testing Market in Asia-Pacific for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.3. Biologics Safety Testing Market in Asia-Pacific for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.4. Biologics Safety Testing Market in Asia-Pacific for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.5. Biologics Safety Testing Market in Asia-Pacific for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.6. Biologics Safety Testing Market in Asia-Pacific for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.7. Biologics Safety Testing Market in Asia-Pacific for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.8. Biologics Safety Testing Market in Asia-Pacific for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.4. Biologics Safety Testing Market in Asia-Pacific: Distribution by Type of Technology
  • 25.4.1. Biologics Safety Testing Market in Asia-Pacific for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.2. Biologics Safety Testing Market in Asia-Pacific for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.3. Biologics Safety Testing Market in Asia-Pacific for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.4. Biologics Safety Testing Market in Asia-Pacific for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.5. Biologics Safety Testing Market in Asia-Pacific for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.5. Biologics Safety Testing Market in Asia-Pacific: Distribution by End-user
  • 25.5.1. Biologics Safety Testing Market in Asia-Pacific for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.5.2. Biologics Safety Testing Market in Asia-Pacific for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.5.3. Biologics Safety Testing Market in Asia-Pacific for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

26 MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

• 26.1. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Offering
  • 26.1.1. Biologics Safety Testing Market in Middle East and North Africa for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.1.2. Biologics Safety Testing Market in Middle East and North Africa for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.1.3. Biologics Safety Testing Market in Middle East and North Africa for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.2. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Testing
  • 26.2.1. Biologics Safety Testing Market in Middle East and North Africa for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.2. Biologics Safety Testing Market in Middle East and North Africa for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.3. Biologics Safety Testing Market in Middle East and North Africa for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.4. Biologics Safety Testing Market in Middle East and North Africa for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.5. Biologics Safety Testing Market in Middle East and North Africa for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.2.6. Biologics Safety Testing Market in Middle East and North Africa for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.3. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Modality
  • 26.3.1. Biologics Safety Testing Market in Middle East and North Africa for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.2. Biologics Safety Testing Market in Middle East and North Africa for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.3. Biologics Safety Testing Market in Middle East and North Africa for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.4. Biologics Safety Testing Market in Middle East and North Africa for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.5. Biologics Safety Testing Market in Middle East and North Africa for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.6. Biologics Safety Testing Market in Middle East and North Africa for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.7. Biologics Safety Testing Market in Middle East and North Africa for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.3.8. Biologics Safety Testing Market in Middle East and North Africa for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.4. Biologics Safety Testing Market in Middle East and North Africa: Distribution by Type of Technology
  • 26.4.1. Biologics Safety Testing Market in Middle East and North Africa for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.2. Biologics Safety Testing Market in Middle East and North Africa for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.3. Biologics Safety Testing Market in Middle East and North Africa for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.4. Biologics Safety Testing Market in Middle East and North Africa for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.5. Biologics Safety Testing Market in Middle East and North Africa for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.5. Biologics Safety Testing Market in Middle East and North Africa: Distribution by End-user
  • 26.5.1. Biologics Safety Testing Market in Middle East and North Africa for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.5.2. Biologics Safety Testing Market in Middle East and North Africa for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.5.3. Biologics Safety Testing Market in Middle East and North Africa for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

27 MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

• 27.1. Biologics Safety Testing Market in Latin America: Distribution by Type of Offering
  • 27.1.1. Biologics Safety Testing Market in Latin America for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.1.2. Biologics Safety Testing Market in Latin America for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.1.3. Biologics Safety Testing Market in Latin America for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.2. Biologics Safety Testing Market in Latin America: Distribution by Type of Testing
  • 27.2.1. Biologics Safety Testing Market in Latin America for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.2. Biologics Safety Testing Market in Latin America for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.3. Biologics Safety Testing Market in Latin America for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.4. Biologics Safety Testing Market in Latin America for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.5. Biologics Safety Testing Market in Latin America for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.2.6. Biologics Safety Testing Market in Latin America for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.3. Biologics Safety Testing Market in Latin America: Distribution by Type of Modality
  • 27.3.1. Biologics Safety Testing Market in Latin America for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.2. Biologics Safety Testing Market in Latin America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.3. Biologics Safety Testing Market in Latin America for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.4. Biologics Safety Testing Market in Latin America for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.5. Biologics Safety Testing Market in Latin America for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.6. Biologics Safety Testing Market in Latin America for Traditional-viral based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.7. Biologics Safety Testing Market in Latin America for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.3.8. Biologics Safety Testing Market in Latin America for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.4. Biologics Safety Testing Market in Latin America: Distribution by Type of Technology
  • 27.4.1. Biologics Safety Testing Market in Latin America for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.2. Biologics Safety Testing Market in Latin America for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.3. Biologics Safety Testing Market in Latin America for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.4. Biologics Safety Testing Market in Latin America for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.5. Biologics Safety Testing Market in Latin America for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.5. Biologics Safety Testing Market in Latin America: Distribution by End-user
  • 27.5.1. Biologics Safety Testing Market in Latin America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.5.2. Biologics Safety Testing Market in Latin America for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.5.3. Biologics Safety Testing Market in Latin America for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• *Detailed information on Chapter 23 to 27 is available in the Excel Data Packs shared along with the report**

28 PORTER'S FIVE FORCES ANALYSIS

• 28.1. Chapter Overview
  • 28.1.1. Significance of Porter's Five Forces Analysis
  • 28.1.2. Porter's Five Forces Analysis
• 28.2. Methodology
• 28.3. Key Parameters
  • 28.3.1. Threats of New Entrants
  • 28.3.2. Bargaining Power of Buyers
  • 28.3.3. Bargaining Power of Solution Providers
  • 28.3.4. Threat of Substitute Solutions
  • 28.3.5. Rivalry Among Existing Competitors
• 28.4. Porter's Five Force Analysis: Harvey Ball Analysis

29 CONCLUDING INSIGHTS

30 EXECUTIVE INSIGHTS

31 APPENDIX I: TABULATED DATA

32 APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List of Tables

• Table 7.1 List of Biologics Safety Testing Service Providers
• Table 7.2 List of Biologics Safety Testing Solution Providers
• Table 11.1 BioMerieux: Service Portfolio
• Table 11.2 BioMerieux: Recent Developments and Future Outlook
• Table 11.3 Charles River Laboratories: Service Portfolio
• Table 11.4 Charles River Laboratories: Recent Developments and Future Outlook
• Table 11.5 Clean Cells: Service Portfolio
• Table 11.6 Clean Cells: Recent Developments and Future Outlook
• Table 11.7 Eurofins: Service Portfolio
• Table 11.8 Eurofins: Developments and Future Outlook
• Table 11.9 Genezen: Service Portfolio
• Table 11.10 SGS: Service Portfolio
• Table 11.11 SGS: Developments and Future Outlook
• Table 11.12 Solvias: Service Portfolio
• Table 11.13 Texcell: Service Portfolio
• Table 11.14 Vimta Labs: Service Portfolio
• Table 11.15 Wickham Micro: Service Portfolio
• Table 12.1 List of Partnerships and Collaborations, Since 2020
• Table 13.1 List of Funding and Investments, Since 2019
• Table 14.1 List of Published Patents, Since 2020
• Table 26.1 Biologics Safety Testing Service Providers: Distribution by Year of Establishment
• Table 26.2 Biologics Safety Testing Service Providers: Distribution by Company Size
• Table 26.3 Biologics Safety Testing Service Providers: Distribution by Location of Headquarters
• Table 26.4 Biologics Safety Testing Service Providers: Distribution by Certification / Accreditation
• Table 26.5 Biologics Safety Testing Service Providers: Distribution by Type of Service Offered
• Table 26.6 Biologics Safety Testing Service Providers: Distribution by Type of Modality
• Table 26.7 Biologics Safety Testing Service Providers: Distribution by Type of Sample Supported
• Table 26.8 Biologics Safety Testing Service Providers: Distribution by Type of Technology
• Table 26.9 Biologics Safety Testing Service Providers: Distribution by End-user
• Table 26.10 Biologics Safety Testing Solution Providers: Distribution by Year of Establishment
• Table 26.11 Biologics Safety Testing Solution Providers: Distribution by Company Size
• Table 26.12 Biologics Safety Testing Solution Providers: Distribution by Location of Headquarters
• Table 26.13 Biologics Safety Testing Solution Providers: Distribution by Type of Offering
• Table 26.14 Biologics Safety Testing Solution Providers: Distribution by Type of Testing
• Table 26.15 Biologics Safety Testing Solution Providers: Distribution by Type of Modality
• Table 26.16 Biologics Safety Testing Solution Providers: Distribution by Type of Sample Analyzed
• Table 26.17 Biologics Safety Testing Solution Providers: Distribution by Type of Technology
• Table 26.18 Biologics Safety Testing Solution Providers: Distribution by Application Area
• Table 26.19 Biologics Safety Testing Solution Providers: Distribution by End-user
• Table 26.20 BioMerieux: Financial Information, Since FY 2022 (EUR Million)
• Table 26.21 Charles River Laboratories: Financial Information, Since FY 2022 (USD Million)
• Table 26.22 Eurofins: Annual Revenues, Financial Information, Since FY 2022 (EUR Million)
• Table 26.23 SGS: Financial Information, Since FY 2022 (CHF Billion)
• Table 26.24 Vimta Labs: Financial Information, Since FY 2022 (INR Million)
• Table 26.25 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2020
• Table 26.26 Partnerships and Collaborations: Distribution by Type of Partnership
• Table 26.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Table 26.28 Partnerships and Collaborations: Distribution by Type of Biologic
• Table 26.29 Partnerships and Collaborations: Distribution by Type of Testing
• Table 26.30 Partnerships and Collaborations: Distribution by Type of Partner
• Table 26.31 Most Active Players: Distribution by Number of Partnerships
• Table 26.32 Partnerships and Collaborations: Local and International Agreements
• Table 26.33 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
• Table 26.34 Funding and Investments Cumulative Year-wise Trend, Since 2019
• Table 26.35 Funding and Investments: Distribution of Instances by Type of Funding
• Table 26.36 Funding and Investments: Distribution of Instances by Year and Type of Funding
• Table 26.37 Funding and Investments: Distribution of Amount by Year of Funding
• Table 26.38 Funding and Investments: Distribution of Amount by Type of Funding
• Table 26.39 Funding and Investments: Distribution by Geography
• Table 26.40 Key Industry Players: Analysis by Number of Funding Instances
• Table 26.41 Most Active Players: Analysis by Amount Invested
• Table 26.42 Most Active Investors: Analysis by Number of Funding Instances
• Table 26.43 Patent Analysis: Distribution by Publication Year
• Table 26.44 Patent Analysis: Distribution by Type of Patent
• Table 26.45 Patent Analysis: Distribution by Patent Application Year
• Table 26.46 Patent Analysis: Distribution by Patent Age
• Table 26.47 Patent Analysis: Distribution by Type of Applicant
• Table 26.48 Patent Analysis: Distribution by Patent Jurisdiction
• Table 26.49 Leading Industry Players: Analysis by Number of Patents
• Table 26.50 Leading Non-Industry Players: Analysis by Number of Patents
• Table 26.51 Leading Individual Assignees: Analysis by Number of Patents
• Table 26.52 Biologics Safety Testing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035): Base Scenario (USD Million)
• Table 26.53 Biologics Safety Testing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
• Table 26.54 Biologics Safety Testing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
• Table 26.55 Biologics Safety Testing Market: Distribution by Type of Offering, Current Year, 2030 and 2035
• Table 26.56 Biologics Safety Testing Market for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.57 Biologics Safety Testing Market for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.58 Biologics Safety Testing Market for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.59 Biologics Safety Testing Market: Distribution by Type of Testing, Current Year, 2030 and 2035
• Table 26.60 Biologics Safety Testing Market for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.61 Biologics Safety Testing Market for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.62 Biologics Safety Testing Market for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.63 Biologics Safety Testing Market for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.64 Biologics Safety Testing Market for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.65 Biologics Safety Testing Market for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.66 Biologics Safety Testing Market: Distribution by Type of Modality, Current Year, 2030 and 2035
• Table 26.67 Biologics Safety Testing Market for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.68 Biologics Safety Testing Market for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.69 Biologics Safety Testing Market for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.70 Biologics Safety Testing Market for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.71 Biologics Safety Testing Market for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.72 Biologics Safety Testing Market for Traditional viral-based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.73 Biologics Safety Testing Market for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.74 Biologics Safety Testing Market for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.75 Biologics Safety Testing Market: Distribution by Type of Technology, Current Year, 2030 and 2035
• Table 26.76 Biologics Safety Testing Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.77 Biologics Safety Testing Market for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.78 Biologics Safety Testing Market for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.79 Biologics Safety Testing Market for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.80 Biologics Safety Testing Market for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.81 Biologics Safety Testing Market: Distribution by End-user, Current Year, 2030 and 2035
• Table 26.82 Biologics Safety Testing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.83 Biologics Safety Testing Market for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.84 Biologics Safety Testing Market for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.85 Biologics Safety Testing Market: Distribution by Geographical Regions, Current Year, 2030 and 2035
• Table 26.86 Biologics Safety Testing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.87 Biologics Safety Testing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.88 Biologics Safety Testing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.89 Biologics Safety Testing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.90 Biologics Safety Testing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.91 Biologics Safety Testing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.92 Biologics Safety Testing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.93 Biologics Safety Testing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.94 Biologics Safety Testing Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.95 Biologics Safety Testing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.96 Biologics Safety Testing Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.97 Biologics Safety Testing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.98 Biologics Safety Testing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.99 Biologics Safety Testing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.100 Biologics Safety Testing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.101 Biologics Safety Testing Market in Rest of Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.102 Biologics Safety Testing Market in Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.103 Biologics Safety Testing Market in Saudi Arabia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.104 Biologics Safety Testing Market in Egypt, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.105 Biologics Safety Testing Market in Rest of Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.106 Biologics Safety Testing Market in Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.107 Biologics Safety Testing Market in Brazil, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.108 Biologics Safety Testing Market in Argentina, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Table 26.109 Biologics Safety Testing Market in Rest of Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

List of Figures

• Figure 2.1 Research Methodology: Project Methodology
• Figure 2.2 Research Methodology: Data Sources for Secondary Research
• Figure 2.3 Research Methodology: Robust Quality Control
• Figure 3.1 Market Dynamics: Forecast Methodology
• Figure 3.2 Market Dynamics: Market Assessment Framework
• Figure 4.1 Lessons Learnt from Past Recessions
• Figure 5.1 Executive Summary: Market Landscape
• Figure 5.2 Executive Summary: Market Trends
• Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
• Figure 7.1 Biologics Safety Testing Service Providers: Distribution by Year of Establishment
• Figure 7.2 Biologics Safety Testing Service Providers: Distribution by Company Size
• Figure 7.3 Biologics Safety Testing Service Providers: Distribution by Location of Headquarters
• Figure 7.4 Biologics Safety Testing Service Providers: Distribution by Certification / Accreditation
• Figure 7.5 Biologics Safety Testing Service Providers: Distribution by Type of Service Offered
• Figure 7.6 Biologics Safety Testing Service Providers: Distribution by Type of Modality
• Figure 7.7 Biologics Safety Testing Service Providers: Distribution by Type of Sample Supported
• Figure 7.8 Biologics Safety Testing Service Providers: Distribution by Type of Technology
• Figure 7.9 Biologics Safety Testing Service Providers: Distribution by End-user
• Figure 8.1 Company Competitiveness Analysis: Biologics Safety Testing Service Providers Offering Services for Vaccines
• Figure 8.2 Company Competitiveness Analysis: Biologics Safety Testing Service Providers Offering Services for Cell Therapies
• Figure 8.3 Company Competitiveness Analysis: Biologics Safety Testing Service Providers Offering Services for Gene Therapies
• Figure 8.4 Company Competitiveness Analysis: Biologics Safety Testing Service Providers Offering Services for Antibodies
• Figure 8.5 Company Competitiveness Analysis: Biologics Safety Testing Service Providers Offering Services for Proteins
• Figure 8.6 Company Competitiveness Analysis: Biologics Safety Testing Service Providers Offering Services for Other Modalities
• Figure 9.1 Biologics Safety Testing Solution Providers: Distribution by Year of Establishment
• Figure 9.2 Biologics Safety Testing Solution Providers: Distribution by Company Size
• Figure 9.3 Biologics Safety Testing Solution Providers: Distribution by Location of Headquarters
• Figure 9.4 Biologics Safety Testing Solution Providers: Distribution by Type of Offering
• Figure 9.5 Biologics Safety Testing Solution Providers: Distribution by Type of Testing
• Figure 9.6 Biologics Safety Testing Solution Providers: Distribution by Type of Modality
• Figure 9.7 Biologics Safety Testing Solution Providers: Distribution by Type of Sample Analyzed
• Figure 9.8 Biologics Safety Testing Solution Providers: Distribution by Type of Technology
• Figure 9.9 Biologics Safety Testing Solution Providers: Distribution by Application Area
• Figure 9.10 Biologics Safety Testing Solution Providers: Distribution by End-user
• Figure 10.1 Company Competitiveness Analysis: Biologics Safety Testing Solution Providers Headquartered in North America
• Figure 10.2 Company Competitiveness Analysis: Biologics Safety Testing Solution Providers Headquartered in Europe
• Figure 10.3 Company Competitiveness Analysis: Biologics Safety Testing Solution Providers Headquartered in Asia-Pacific and Rest of the world
• Figure 11.1 BioMerieux: Annual Revenues, Since FY 2022 (EUR Million)
• Figure 11.2 Charles River Laboratories: Annual Revenues, Since FY 2022 (USD Million)
• Figure 11.3 Eurofins: Annual Revenues, Since FY 2022 (EUR Million)
• Figure 11.4 SGS: Annual Revenues, Since FY 2022 (CHF Billion)
• Figure 11.5 Vimta Labs: Annual Revenues, Since FY 2022 (INR Million)
• Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2020
• Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
• Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Figure 12.4 Partnerships and Collaborations: Distribution by Type of Biologic
• Figure 12.5 Partnerships and Collaborations: Distribution by Type of Testing
• Figure 12.6 Partnerships and Collaborations: Distribution by Type of Partner
• Figure 12.7 Most Active Players: Distribution by Number of Partnerships
• Figure 12.8 Partnerships and Collaborations: Local and International Agreements
• Figure 12.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
• Figure 13.1 Funding and Investments: Cumulative Year-wise Trend, Since 2019
• Figure 13.2 Funding and Investments: Distribution of Instances by Type of Funding
• Figure 13.3 Funding and Investments: Distribution of Instances by Year and Type of Funding
• Figure 13.4 Funding and Investments: Distribution of Amount by Year of Funding
• Figure 13.5 Funding and Investments: Distribution of Amount by Type of Funding
• Figure 13.6 Funding and Investments: Distribution by Geography
• Figure 13.7 Key Industry Players: Analysis by Number of Funding Instances
• Figure 13.8 Most Active Players: Analysis by Amount Invested
• Figure 13.9 Most Active Investors: Analysis by Number of Funding Instances
• Figure 13.10 Summary of Investments
• Figure 14.1 Patent Analysis: Distribution by Publication Year
• Figure 14.2 Patent Analysis: Distribution by Type of Patent
• Figure 14.3 Patent Analysis: Distribution by Patent Application Year
• Figure 14.4 Patent Analysis: Distribution by Patent Age
• Figure 14.5 Patent Analysis: Distribution by Type of Applicant
• Figure 14.6 Patent Analysis: Distribution by Patent Jurisdiction
• Figure 14.7 Patent Analysis: Distribution by CPC Symbols
• Figure 14.8 Leading Industry Players: Analysis by Number of Patents
• Figure 14.9 Leading Non-Industry Players: Analysis by Number of Patents
• Figure 14.10 Leading Individual Assignees: Analysis by Number of Patents
• Figure 16.1 Biologics Safety Testing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035): Base Scenario (USD Million)
• Figure 16.2 Biologics Safety Testing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
• Figure 16.3 Biologics Safety Testing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
• Figure 17.1 Biologics Safety Testing Market: Distribution by Type of Offering, Current Year, 2030 and 2035
• Figure 17.2 Biologics Safety Testing Market for Consumables, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 17.3 Biologics Safety Testing Market for Instruments, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 17.4 Biologics Safety Testing Market for Services, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 18.1 Biologics Safety Testing Market: Distribution by Type of Testing, Current Year, 2030 and 2035
• Figure 18.2 Biologics Safety Testing Market for Virus Safety Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 18.3 Biologics Safety Testing Market for Mycoplasma Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 18.4 Biologics Safety Testing Market for Sterility Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 18.5 Biologics Safety Testing Market for Endotoxin Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 18.6 Biologics Safety Testing Market for Bioburden Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 18.7 Biologics Safety Testing Market for Other Testing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.1 Biologics Safety Testing Market: Distribution by Type of Modality, Current Year, 2030 and 2035
• Figure 19.2 Biologics Safety Testing Market for Antibodies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.3 Biologics Safety Testing Market for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.4 Biologics Safety Testing Market for Cell Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.5 Biologics Safety Testing Market for Gene Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.6 Biologics Safety Testing Market for Biosimilars, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.7 Biologics Safety Testing Market for Traditional viral-based Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.8 Biologics Safety Testing Market for Proteins, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 19.9 Biologics Safety Testing Market for Other Modalities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 20.1 Biologics Safety Testing Market: Distribution by Type of Technology, Current Year, 2030 and 2035
• Figure 20.2 Biologics Safety Testing Market for Polymerase Chain Reaction, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 20.3 Biologics Safety Testing Market for Traditional Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 20.4 Biologics Safety Testing Market for Chromatographic and Electrophoretic Techniques, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 20.5 Biologics Safety Testing Market for Next-Generation Sequencing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 20.6 Biologics Safety Testing Market for Other Technologies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 21.1 Biologics Safety Testing Market: Distribution by End-user, Current Year, 2030 and 2035
• Figure 21.2 Biologics Safety Testing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 21.3 Biologics Safety Testing Market for Contract Research Organizations / Contract Development and Manufacturing Organizations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 21.4 Biologics Safety Testing Market for Academic and Research Institutes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.1 Biologics Safety Testing Market: Distribution by Geographical Regions, Current Year, 2030 and 2035
• Figure 22.2 Biologics Safety Testing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.3 Biologics Safety Testing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.4 Biologics Safety Testing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.5 Biologics Safety Testing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.6 Biologics Safety Testing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.7 Biologics Safety Testing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.8 Biologics Safety Testing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.9 Biologics Safety Testing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.10 Biologics Safety Testing Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.11 Biologics Safety Testing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.12 Biologics Safety Testing Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.13 Biologics Safety Testing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.14 Biologics Safety Testing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.15 Biologics Safety Testing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.16 Biologics Safety Testing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.17 Biologics Safety Testing Market in Rest of Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.18 Biologics Safety Testing Market in Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.19 Biologics Safety Testing Market in Saudi Arabia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.20 Biologics Safety Testing Market in Egypt, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.21 Biologics Safety Testing Market in Rest of Middle East and North Africa, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.22 Biologics Safety Testing Market in Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.23 Biologics Safety Testing Market in Brazil, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.24 Biologics Safety Testing Market in Argentina, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• Figure 22.25 Biologics Safety Testing Market in Rest of Latin America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)